Phase I/II clinical trial to assess the safety and biological efficacy of treatment with virus-specific, cytotoxic T-lymphocytes from partially matched third-party unrelated donors, in stem cell transplant patients with viral reactivation unresponsive to standard therapy (R3ACT trial)

This study is testing whether immune cells from a partially matched donor can be used to fight serious viral infections in people who have had a stem cell or bone marrow transplant. Transplant patients often develop infections with viruses like CMV, adenovirus, or EBV that do not respond to standard antiviral treatments. Researchers are testing whether infusing virus-fighting immune cells (called cytotoxic T-lymphocytes) from a donor bank can safely restore the patient's ability to fight these viruses. You may be eligible if: - You have received an allogeneic (from another person) stem cell or bone marrow transplant - You have a serious viral infection with CMV, adenovirus, or EBV that has not responded to standard treatment - Your liver and kidney function are at acceptable levels - Your performance status is ECOG 0–3 You may NOT be eligible if: - You received broad-spectrum anti-lymphocyte therapy in the past 4 weeks or have it planned in the next 4 weeks - You have Grade II or higher graft-versus-host disease - You are on high-dose steroids (prednisone above 1 mg/kg) within 72 hours of treatment - Your ECOG status is 4 (completely disabled) - You are privately insured (depending on the study site) Talk to your doctor about whether this trial might be right for you.